Evidence map›Paper›PMID 41870990›Full record

ArticleAmerican journal of physiology. Cell physiology2026

Enhanced hypoxia resistance distinguishes human pluripotent stem cell-derived islets from primary islets.

Hiroyuki Kato, Kuang-Ming Shang, Hiroaki Mitsugashira, Meirigeng Qi, Tomoharu Suzuki, Peter G Stock, Taro Toyoda, Yu-Chong Tai, Fouad Kandeel, Hirotake Komatsu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of physiology. Cell physiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Hiroyuki KatoDivision of Transplant Surgery, Department of Surgery, University of California, San Francisco, California, United States.ORCID 0000-0001-6839-7663
Kuang-Ming ShangDepartment of Medical Engineering, California Institute of Technology, Pasadena, California, United States.ORCID 0000-0001-5065-7607
Hiroaki MitsugashiraDivision of Transplant Surgery, Department of Surgery, University of California, San Francisco, California, United States.ORCID 0000-0002-2925-1482
Meirigeng QiDepartment of Translational Research & Cellular Therapeutics, Arthur Riggs Diabetes & Metabolism Research Institute of City of Hope, Duarte, California, United States.
Tomoharu SuzukiDepartment of Life Science Frontiers, Center for iPS Cell Research and Application, Kyoto University, Kyoto, Japan.
Peter G StockDivision of Transplant Surgery, Department of Surgery, University of California, San Francisco, California, United States.ORCID 0000-0002-5806-0167
Taro ToyodaDepartment of Life Science Frontiers, Center for iPS Cell Research and Application, Kyoto University, Kyoto, Japan.ORCID 0000-0002-2948-0525
Yu-Chong TaiDepartment of Medical Engineering, California Institute of Technology, Pasadena, California, United States.
Fouad KandeelDepartment of Translational Research & Cellular Therapeutics, Arthur Riggs Diabetes & Metabolism Research Institute of City of Hope, Duarte, California, United States.
Hirotake KomatsuDivision of Transplant Surgery, Department of Surgery, University of California, San Francisco, California, United States.ORCID 0000-0003-0876-4809

Funding

Vascular network-mimetic oxygen-transporting mesh for islet graftR03DK129958 · NIDDK · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI KOMATSU, HIROTAKE · 2021 to 2022
$353k
Breakthrough T1D (JDF) 1-SRA-2025-1635-S-BBreakthrough T1D (JDF) 3-SRA-2025-1634-S-BHHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) R03DK129958-01NIDDK NIH HHS R03 DK129958Nora Eccles Treadwell Foundation
6 · The paper itself

Abstract

Hypoxia during the early posttransplant period represents a major barrier to successful cellular transplantation. This limitation is particularly relevant for pancreatic islet transplantation, a clinical treatment option for diabetes. Stem cell-derived islets are an emerging potential alternative to current primary islets obtained from deceased donors. Although stem cell-derived cells are generally assumed to be more hypoxia-tolerant than primary cells, direct quantitative evidence supporting this assumption has been limited, particularly in comparisons between stem cell-derived islets and primary islets. Here, we applied a recently developed Po

Indexed as

Induced Pluripotent Stem CellsIslets of LangerhansOxygenPluripotent Stem CellsCell DifferentiationCell HypoxiaCells, CulturedCell SurvivalHumansIslets of Langerhans TransplantationSpheroids, CellularOxygengraft survivalhuman primary pancreatic isletshuman stem cell-derived isletshypoxia resistanceoxygen tension

Identifiers

PMID41870990
PMCPMC13132159

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.